Scholar Rock Holding CorporationSRRKNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

seekingalpha.com

Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

seekingalpha.com

Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript

businesswire.com

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the release, the first paragraph of the Fourth Quarter and Full Year 2025 Financial Results section, second sentence should read: Net loss per common share was $0.76 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024. (instead of Net loss per common share was $0.88 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024.) In the Conde.

businesswire.com

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent company de.

fool.com

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%

Redmile Group added 1,316,390 shares of Scholar Rock Holding Corporation in the fourth quarter; the estimated trade value was $49.37 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $84.58 million, reflecting both new purchases and stock price changes.

defenseworld.net

Insider Selling: Scholar Rock (NASDAQ:SRRK) General Counsel Sells $445,757.40 in Stock

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) General Counsel Junlin Ho sold 9,580 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $445,757.40. Following the transaction, the general counsel owned 241,545 shares in the company,

businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provis.

businesswire.com

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telep.

fool.com

Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026

Mo Qatanani sold 14,898 shares directly for a transaction value of approximately $695,938 on Jan. 22, 2026, at a weighted average price of $46.71 per share. The sale represented 14.82% of Qatanani's direct holdings, reducing direct ownership to 85,660 shares, which equates to 0.08% of shares outstanding.

defenseworld.net

12,008 Shares in Scholar Rock Holding Corporation $SRRK Acquired by SG Americas Securities LLC

SG Americas Securities LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,008 shares of the company's stock, valued at approximately $447,000. Other large investors have also recently made

defenseworld.net

Mo Qatanani Sells 13,112 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) insider Mo Qatanani sold 13,112 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $45.20, for a total transaction of $592,662.40. Following the completion of the transaction, the insider owned 108,964 shares

businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an aggregate of 14,800 shares of its common stock. The awards are subject to all terms and conditions and other provision.

seekingalpha.com

Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

businesswire.com

Scholar Rock Highlights 2026 Strategic Priorities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today provided a corporate update and highlighted its strategic priorities for 2026. “We believe 2026 will be a transformative year for Sc.

defenseworld.net

Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Recommendation of “Buy” by Brokerages

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) has been assigned a consensus rating of "Buy" from the sixteen brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and four have given a strong buy recommendation

seekingalpha.com

Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating

I maintain a buy rating on Scholar Rock, raising my target price to $97, reflecting increased confidence in apitegromab's approval and commercial prospects. FDA setbacks are manufacturing-related, not clinical, with no new efficacy or safety concerns; remediation and a second CDMO are underway. Topline phase 3 data support apitegromab's novel mechanism and broad label potential, materially expanding SRRK's addressable market and pricing power.

businesswire.com

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 a.m. PST (.

businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,343 shares of its common stock. The awards are subject to all terms and conditions and other provisions.

defenseworld.net

Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Rating of “Buy” by Brokerages

Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) have earned a consensus rating of "Buy" from the sixteen research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and four have issued a strong buy recommendation

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance